Oragenics, Inc. (OGEN)
USD 0.33
(-2.99%)
USD 0.33
(-2.99%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -15.45 Million USD | -17891.87% |
| 2022 | 86.85 Thousand USD | 89.84% |
| 2021 | 45.75 Thousand USD | 188.48% |
| 2020 | -51.7 Thousand USD | 17.43% |
| 2019 | -62.62 Thousand USD | -107.98% |
| 2018 | -30.11 Thousand USD | 54.24% |
| 2017 | -65.8 Thousand USD | 12.31% |
| 2016 | -75.04 Thousand USD | -110.81% |
| 2015 | 694.09 Thousand USD | 21.7% |
| 2014 | 570.32 Thousand USD | -17.21% |
| 2013 | 688.87 Thousand USD | 51.97% |
| 2012 | 453.3 Thousand USD | -37.97% |
| 2011 | 730.82 Thousand USD | 84.03% |
| 2010 | 397.11 Thousand USD | -5.47% |
| 2009 | 420.08 Thousand USD | 92.11% |
| 2008 | 218.67 Thousand USD | 64.31% |
| 2007 | 133.08 Thousand USD | 101.11% |
| 2006 | 66.17 Thousand USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 196.21 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -906.77 Thousand USD | -36.68% |
| 2024 Q1 | -663.41 Thousand USD | 94.01% |
| 2023 Q3 | 2681.00 USD | 44.14% |
| 2023 Q1 | 5721.00 USD | -95.17% |
| 2023 Q2 | 1860.00 USD | -67.49% |
| 2023 Q4 | -11.07 Million USD | -413364.98% |
| 2023 FY | 10.26 Thousand USD | -88.18% |
| 2022 FY | 86.85 Thousand USD | 89.84% |
| 2022 Q3 | 73.3 Thousand USD | 102.86% |
| 2022 Q4 | 118.44 Thousand USD | 61.59% |
| 2022 Q1 | 6615.00 USD | -91.79% |
| 2022 Q2 | -2.55 Million USD | -38794.5% |
| 2021 Q3 | -9641.00 USD | 22.57% |
| 2021 Q4 | 80.56 Thousand USD | 935.67% |
| 2021 Q1 | -12.72 Thousand USD | 99.94% |
| 2021 Q2 | -12.45 Thousand USD | 2.15% |
| 2021 FY | 45.75 Thousand USD | 188.48% |
| 2020 FY | -51.7 Thousand USD | 17.43% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | -22.1 Million USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | -62.62 Thousand USD | -107.98% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 FY | -30.11 Thousand USD | 54.24% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 100.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | -65.8 Thousand USD | 12.31% |
| 2016 Q4 | -352.21 Thousand USD | 0.0% |
| 2016 FY | -75.04 Thousand USD | -110.81% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | -100.0% |
| 2016 Q1 | 172.3 Thousand USD | 16.53% |
| 2015 Q3 | 195.2 Thousand USD | 25.73% |
| 2015 FY | 694.09 Thousand USD | 21.7% |
| 2015 Q4 | 147.86 Thousand USD | -24.25% |
| 2015 Q2 | 155.25 Thousand USD | -20.7% |
| 2015 Q1 | 195.77 Thousand USD | 50.62% |
| 2014 Q3 | 127.29 Thousand USD | -28.54% |
| 2014 FY | 570.32 Thousand USD | -17.21% |
| 2014 Q1 | 134.9 Thousand USD | -62.04% |
| 2014 Q2 | 178.14 Thousand USD | 32.06% |
| 2014 Q4 | 129.98 Thousand USD | 2.11% |
| 2013 FY | 688.87 Thousand USD | 51.97% |
| 2013 Q3 | 139.99 Thousand USD | 72.8% |
| 2013 Q1 | 112.45 Thousand USD | 322.03% |
| 2013 Q4 | 355.42 Thousand USD | 153.89% |
| 2013 Q2 | 81.01 Thousand USD | -27.96% |
| 2012 Q4 | 26.64 Thousand USD | -73.4% |
| 2012 Q1 | 182.31 Thousand USD | -24.4% |
| 2012 FY | 453.3 Thousand USD | -37.97% |
| 2012 Q2 | 144.14 Thousand USD | -20.94% |
| 2012 Q3 | 100.18 Thousand USD | -30.5% |
| 2011 Q1 | 254.96 Thousand USD | 282.04% |
| 2011 Q4 | 241.16 Thousand USD | 11.68% |
| 2011 Q2 | 18.75 Thousand USD | -92.65% |
| 2011 FY | 730.82 Thousand USD | 84.03% |
| 2011 Q3 | 215.94 Thousand USD | 1051.56% |
| 2010 Q2 | 177.27 Thousand USD | 24.33% |
| 2010 FY | 397.11 Thousand USD | -5.47% |
| 2010 Q4 | -140.05 Thousand USD | -164.45% |
| 2010 Q1 | 142.58 Thousand USD | -8.06% |
| 2010 Q3 | 217.31 Thousand USD | 22.59% |
| 2009 Q4 | 155.08 Thousand USD | 15.55% |
| 2009 FY | 420.08 Thousand USD | 92.11% |
| 2009 Q1 | 112.49 Thousand USD | 100.76% |
| 2009 Q2 | 18.29 Thousand USD | -83.74% |
| 2009 Q3 | 134.21 Thousand USD | 633.77% |
| 2008 Q3 | 100 Thousand USD | 0.0% |
| 2008 Q1 | 125 Thousand USD | 367.41% |
| 2008 FY | 218.67 Thousand USD | 64.31% |
| 2008 Q4 | -14.85 Million USD | -14955.46% |
| 2008 Q2 | - USD | -100.0% |
| 2007 Q2 | 26.67 Thousand USD | -19.39% |
| 2007 Q1 | 33.08 Thousand USD | 0.0% |
| 2007 Q4 | 26.74 Thousand USD | -42.59% |
| 2007 Q3 | 46.58 Thousand USD | 74.65% |
| 2007 FY | 133.08 Thousand USD | 101.11% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | -100.0% |
| 2006 Q3 | 66.17 Thousand USD | 0.0% |
| 2006 FY | 66.17 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | -100.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q2 | 44.23 Thousand USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | 118.64 Thousand USD | 168.21% |
| 2004 Q4 | 33.33 Thousand USD | -71.9% |
| 2004 FY | 196.21 Thousand USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 160 Thousand USD | 9758.094% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -6081.18% |
| Armata Pharmaceuticals, Inc. | -29.24 Million USD | 47.153% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | -2079.542% |
| Azitra, Inc. | 260.45 Thousand USD | 6033.151% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 2179.805% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | -499.087% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | -1130.33% |
| CEL-SCI Corporation | -3.95 Million USD | -290.39% |
| iBio, Inc. | -1.02 Million USD | -1407.605% |
| Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 286.765% |
| MAIA Biotechnology, Inc. | - USD | Infinity% |
| Matinas BioPharma Holdings, Inc. | -13.39 Million USD | -15.381% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -12853.561% |
| NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 295.731% |
| NanoViricides, Inc. | -759.01 Thousand USD | -1935.924% |
| BiomX Inc. | -1.22 Million USD | -1158.384% |
| BiomX Inc. | -1.22 Million USD | -1158.384% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 136.35% |
| Palatin Technologies, Inc. | 4.39 Million USD | 451.807% |
| Scorpius Holdings, Inc. | -2.21 Million USD | -597.204% |